フィラグリン
"The burden of disease associated with filaggrin mutations: a population-based, longitudinal birth cohort study". The Journal of Allergy and Clinical Immunology. 121 (4): 872–7.e9.
Tavendale R, Macgregor DF, Mukhopadhyay S, Palmer CN (April 2008). "A polymorphism controlling ORMDL3 expression is associated with asthma that is poorly controlled by current medications". The Journal of Allergy and Clinical Immunology. 121 (4): 860–3.
Bisgaard H, Simpson A, Palmer CN, Bønnelykke K, McLean I, Mukhopadhyay S, Pipper CB, Halkjaer LB, Lipworth B, Hankinson J, Woodcock A, Custovic A (June 2008). "Gene-environment interaction in the onset of eczema in infancy: filaggrin loss-of-function mutations enhanced by neonatal cat exposure". PLoS Medicine. 5 (6): e131.
Basu K, Palmer CN, Lipworth BJ, McLean WH, Terron-Kwiatkowski A, Zhao Y, Liao H, Smith FJ, Mitra A, Mukhopadhyay S (September 2008). "Filaggrin null mutations are associated with increased asthma exacerbations in children and young adults" . Allergy. 63 (9): 1211–7.
Palmer CN, Ismail T, Lee SP, Terron-Kwiatkowski A, Zhao Y, Liao H, Smith FJ, McLean WH, Mukhopadhyay S (July 2007). "Filaggrin null mutations are associated with increased asthma severity in children and young adults". The Journal of Allergy and Clinical Immunology. 120 (1): 64–8.
Henderson J, Northstone K, Lee SP, Liao H, Zhao Y, Pembrey M, Mukhopadhyay S, Smith GD, Palmer CN, McLean WH, Irvine AD (April 2008).